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Abstract
BACKGROUND—Few African countries separate blood donations into components; however, 
demand for platelets (PLTs) is increasing as regional capacity to treat causes of thrombocytopenia, 
including chemotherapy, increases. Namibia introduced single-donor apheresis PLT collections in 
2007 to increase PLT availability while reducing exposure to multiple donors via pooling. This 
study describes the impact this transition had on PLT availability and safety in Namibia.
STUDY DESIGN AND METHODS—Annual national blood collections and PLT units issued 
data were extracted from a database maintained by the Blood Transfusion Service of Namibia 
(NAMBTS). Production costs and unit prices were analyzed.
RESULTS—In 2006, NAMBTS issued 771 single and pooled PLT doses from 3054 whole blood 
(WB) donations (drawn from 18,422 WB donations). In 2007, NAMBTS issued 486 single and 
pooled PLT doses from 1477 WB donations (drawn from 18,309 WB donations) and 131 single-
donor PLT doses. By 2011, NAMBTS issued 837 single-donor PLT doses per year, 99.1% of all 
PLT units. Of 5761 WB donations from which PLTs were made in 2006 to 2011, a total of 20 
(0.35%) were from donors with confirmed test results for human immunodeficiency virus or other 
transfusion-transmissible infections (TTIs). Of 2315 single-donor apheresis donations between 
2007 and 2011, none of the 663 donors had a confirmed positive result for any pathogen. As 
apheresis replaced WB-derived PLTs, apheresis production costs dropped by a mean of 8.2% per 
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year, while pooled PLT costs increased by an annual mean of 21.5%. Unit prices paid for 
apheresis- and WB-derived PLTs increased by 9 and 7.4% per year on average, respectively.
CONCLUSION—Namibia’s PLT transition shows that collections from repeat apheresis donors 
can reduce TTI risk and production costs.
In sub-Saharan Africa, most blood transfusions are performed with whole blood (WB), and 
fewer than half of countries report separating any collected blood units into components.1 
Reasons for reliance on WB transfusions include transportation, inventory management and 
cold chain challenges, inadequate storage capacity, clinicians’ inexperience in the 
appropriate use of blood components, and limited financial resources to support blood 
component production facilities.2–7 In developed countries, platelet (PLT) transfusions are 
most frequently indicated for hematologic and oncologic conditions complicated by 
thrombocytopenia.8–10 While obstetric hemorrhage, malaria-related anemia, and trauma 
have historically accounted for most transfusions in sub- Saharan Africa, increased numbers 
of patients with hematologic conditions and other malignancies are expected due to 
improved diagnostic and clinical capacity.11–15 As blood banking capabilities in the region 
continue to develop, there has been growing emphasis on the preparation of blood 
components, including PLTs, to effectively manage thrombocytopenia due to malignancy or 
chemotherapy-related complications.16,17
In Namibia, a medium human development index country in southern Africa with a high 
human immunodeficiency virus (HIV) burden, the Blood Transfusion Service of Namibia 
(NAMBTS), a nonprofit organization that funds the majority of its operations through a 
cost-recovery system, is the only entity authorized to collect, process, and distribute blood 
and blood components, including PLTs. Nearly all transfusions in the country occur with 
components rather than WB. NAMBTS only collects blood from voluntary, nonremunerated 
blood donors (VNRDs) and prepares PLTs from repeat VNRDs who have made at least two 
previous donations, a group considered at lowest risk for HIV infection.18,19
The country has relatively small numbers of cancer diagnoses annually. Between 2006 and 
2011, the Cancer Association of Namibia documented 13,652 new cases of adult cancers 
(unpublished data, Cancer Association of Namibia). Patients have historically been referred 
to neighboring South Africa for treatment;20–22 however, increasingly, therapy for 
hematologic and other malignancies is provided in Namibia.20 To meet the national demand 
for PLTs, NAMBTS initially prepared WB-derived PLTs using the buffy coat method.23 In 
2007, however, NAMBTS procured apheresis equipment and began single-donor apheresis 
PLT collections. The decision to transition from WB-derived PLTs pooled from several 
donors to single-donor apheresis PLTs was driven by concern about Namibia’s high HIV 
adult (ages 15–49) population prevalence, which ranged from an estimated 15.7% in 2002 
and 2003 to an estimated 13.5% in 2010 and 2011,24 and a desire to reduce the risk of 
transfusion-transmitted infections (TTIs) associated with exposure to multiple donors.25
While Namibia’s annual production of PLTs is small compared to industrialized countries, 
the evolution of NAMBTS’s PLT collection and production practices may provide useful 
lessons for other countries in the region considering implementing or expanding PLT 
production. This assessment of Namibia’s transition to apheresis PLT collections provides 
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strong evidence of the increased safety of highly regular apheresis donors, a rare group of 
repeat blood donors in sub-Saharan Africa, and quantifies and describes the current demand 
for PLTs in an African health care system. Finally, investments in apheresis PLT production 
in Namibia have had important cost and sustainability implications for Namibia, which may 
be relevant to other countries in the region.
MATERIALS AND METHODS
Approval was obtained from the Namibian Ministry of Health and Social Services 
(MOHSS) before data collection. Because data were collected as part of routine public 
health program activities, the project was exempted from review by an institutional review 
board by the Centers for Disease Control and Prevention in Atlanta, Georgia.
Study sites and data collection
Demographic, clinical, and laboratory data are routinely collected on all NAMBTS blood 
donors, including the type of collection (WB or apheresis), infectious disease screening 
results, the number of previous donations, and the number and type of components produced 
from each collection. Some limited information on transfusion recipients, including 
diagnosis and patient demographics, is regularly recorded on blood request forms, which 
were last updated in 2007. Blood donor, laboratory screening, and PLT production data are 
stored in an electronic, NAMBTS-designed SQL database, which also captures information 
on blood requests from facilities.
To describe the transition of PLT production from WB collections to apheresis and to 
calculate the prevalence of TTIs among the two groups of PLT donors, a data set containing 
information on donor demographics, donation type (WB or apheresis), and TTI results was 
extracted from the database for all donations between January 1, 2006, and December 31, 
2011. The safety of WB-derived and apheresis PLT collections was further documented by 
the incidence of TTI between WB and apheresis donors. An additional assessment of safety 
was determined by estimating the residual risk of HIV, hepatitis B virus (HBV), and 
hepatitis C virus (HCV) transmission via transfusion attributable to both product types using 
a previously described incidence rate/window period model.26 For this study, the incidence 
rates and residual risk of transfusion-transmitted HIV, HBV, and HCV could not be 
calculated for donations between 2006 and 2011 because information on interdonation 
intervals and person-years of observation were not available for the incidence rate estimate 
calculation. However, since donor demographics remained stable from 2006 and 2013, and 
there were no changes to donor recruitment, deferral criteria, or the TTI screening algorithm, 
an alternative, representative, period (February 1, 2012–June 30, 2013) for which data on 
interdonation intervals were available was used to calculate residual risk. Because 
NAMBTS had stopped production of pooled PLT units by 2012, the residual risk of 
transmission among WB donors was modeled using the former eligibility criteria for WB 
donations to be selected for pooled PLT production. (To be selected for pooled PLT 
production, a WB donor must have had three previous TTI-negative donations recorded in 
the NAMBTS database, at least one of which must have occurred within the previous 6 
months.)
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Pooled adult PLT doses were prepared by combining five WB-derived PLT units resulting 
in a product with a mean volume of 275 to 300 mL and expected PLT count of more than 
240 × 109/L. A pediatric dose is a single, unpooled, WB-derived PLT unit with a mean 
volume of 50 to 60 mL and a PLT count of more than 55 × 109/L. Adult apheresis doses 
were collected from a single donor in 200- to 300-mL bags using apheresis equipment 
(Haemonetics MCS+9000, Haemonetics Corp., Braintree, MA). Each apheresis dose had an 
expected PLT count of more than 300 × 109/L. All PLTs were collected and produced at the 
NAMBTS blood center in Windhoek.
All TTI screening was performed by the South African National Blood Service, which uses 
an algorithm combining immunoassays and individual-donation nucleic acid tests (ID-NAT) 
for HIV, HBV, and HCV screening and confirmatory testing and Treponema pallidum 
hemagglutination assay (TPHA) for syphilis screening.27 An infected donor was defined as 
a PLT donor with a repeat-reactive serologic test plus a confirmed ID-NAT for HIV, HBV 
or HCV, or a positive TPHA result.
Blood request data, including underlying patient diagnoses, are captured by blood banks 
nationally and returned on a routine basis to NAMBTS headquarters. For this study, the total 
number of all PLT units requested and issued to health care facilities nationally were 
extracted for all years (2006–2011). To describe national demand for PLTs, 4 years (2007–
2011) of electronic PLT request records that included patient diagnosis information were 
reviewed. The standardized national blood request form requires physicians to enter a 
diagnosis for each patient, but physicians are not required to use a standard set of diagnostic 
codes or terms. For this analysis, more than 200 individual diagnoses entered by physicians 
were reviewed by one of the coinvestigators (SB) and grouped into 20 broad diagnostic 
categories defined by the WHO International Classification of Disease system (ICD-10).28
To evaluate the impact of introducing apheresis collections on unit prices charged to public 
sector hospitals via the NAMBTS cost-recovery system, invoice data were extracted from an 
electronic accounting system used by NAMBTS. The analysis was limited to the public 
sector since MOHSS-operated facilities accounted for a mean of 77% of all PLT units issued 
each year. Prices are set annually by NAMBTS in consultation with the MOHSS and are 
derived from a costing algorithm that divides the sum of all production costs (including 
waste) minus any non–cost-recovery revenue (e.g., external grants) by the total number of 
PLT units produced each year.29 This model assigns fixed costs across all of the product 
categories and accounts for differences in the amount of labor, utilities, and other variables 
required to produce different types of blood components (e.g., red blood cells or buffy coat 
pooled PLTs). In this way, unit costs associated with “pooled PLTs” reflect the additional 
inputs related to the PLT extraction and pooling processes, whereas “whole blood” unit 
costs do not. Pooled PLT costs and prices were analyzed for 2006 to 2011. Because the 
accounting database does not match the calendar year, 2008 was the first full year for which 
apheresis unit costs and prices were available for analysis. Similarly, because cost data 
reflect actual prices paid for goods and services during each year, all analyses were 
conducted using unadjusted Namibian dollars. Mean annual US dollar exchange rates are 
provided in Table 1.
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Data were stratified by sex, age, type of donation, and year. Descriptive statistics were 
calculated with computer software (Microsoft Excel, Microsoft Corp., Seattle, WA; Stata 
13.1, StataCorp., College Station, TX). National population estimates were drawn from the 
Namibian Central Bureau of Statistics.30
RESULTS
Donor demographics
Between 2006 and 2011, NAMBTS produced WB-derived PLT units from 4173 WB 
donors. Of these, 2473 (59%) were males; the mean age was 40.1 years (range, 16–73 
years). From 2007 to 2011, a total of 663 donors made apheresis PLT donations. Of these, 
399 (60.2%) were males; the mean age was 43.2 years (range, 19–66 years).
From 2006 to 2011, a total of 5761 WB donations from 4173 donors were converted into 
PLT units. Among this donor pool, the mean number of donations per donor per year was 
1.2 (range, 1.5 in 2006 to 1 in 2011). By contrast, among apheresis PLT donors, a mean of 
5.0 donations were made per year between 2007 and 2011 (range, 2.9 in 2007 to 6.7 in 
2010). From 2006 to 2011, of 5761 WB donations from which PLT units were derived, 20 
(0.3%) were from donors with laboratory confirmed results for one or more TTIs (Table 1). 
Of these, 12 donations (60%) were from male donors. No confirmed TTIs were detected 
among 663 apheresis PLT donors between 2007 and 2011 (Table 1).
Incidence rate and residual risk
Between February 1, 2012, and June 30, 2013, the alternative period for which person-years 
of exposure were available for all donor records, 903 apheresis and 17,330 eligible WB 
donations were made in Windhoek. Among the 17,330 WB donations that met the eligibility 
criteria to be selected for buffy coat pooled PLT production, HIV, HBV, and HCV 
infections were confirmed by ID-NAT in 10 (0.06%), two (0.01%), and zero (0.0%) 
donations, respectively. None of the 903 single-donor apheresis donations had an ID-NAT 
confirmed-positive result for any of the three viral markers (Table 2). Incidence rates per 
10,000 donations and residual risk estimates for each marker and the two donation groups 
are shown in Table 2.
In 2006, NAMBTS issued 771 WB-derived PLT doses (341 pooled adult doses, 430 
pediatric doses). Apheresis PLT collections were introduced in 2007. During that year, 
NAMBTS issued 241 WB-derived PLT doses (218 pooled adult doses, 23 pediatric doses) 
and 245 apheresis PLT doses (130 adult, 115 pediatric). WB-derived pooled units were 
almost eliminated by 2011, when only eight pooled PLT units were issued nationally. By 
2011, NAMBTS produced and issued 837 apheresis PLT doses (324 pediatric units, 513 
adult units). As a proportion of all PLT units issued per year, single-donor apheresis doses 
accounted for 37% (245/662) of all PLT doses issued in 2007, but 99.1% (837/845) of all 
PLT doses issued in 2011 (Fig. 1). Although 39 health care facilities (including 29 public 
hospitals) requested PLTs between 2006 and 2011 (annual range, 20–25 facilities per year), 
64.2% of all requests were from two large public, tertiary referral hospitals in the capital, 
Windhoek.
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Patient diagnosis data from blood request forms were routinely captured by the NAMBTS 
information system starting in 2007. Between 2007 and 2011, a total of 4015 PLT doses 
were issued to hospitals nationally (Fig. 1). Of these, 1199 (30%) were given to patients 
with ICD-10 diagnoses associated with “malignant neoplasms” (C00–C97) and “aplastic 
anemia” (D50–D64), which collectively accounted for the highest proportion of all 
diagnoses.
The cost to produce an adult WB-derived pooled PLT dose increased by a mean of 21.5% 
per year between 2006 and 2011 (Table 1). As apheresis donations accounted for an 
increasing proportion of all PLT units produced by NAMBTS, production costs for adult 
apheresis doses declined by a mean of 8.2% per year between 2008 and 2011 (Table 1). 
During the study period, unit prices for WB-derived doses and apheresis doses increased by 
a mean of 7.4 and 9.0% per year. By 2011, as the production of WB-derived PLTs fell to 
nearly zero, nonapheresis PLTs cost more to produce than the cost-recovery price.
DISCUSSION
Investments in apheresis technology allowed NAMBTS to improve the availability and, 
likely, the safety of PLTs in Namibia by collecting PLTs from a core population of reliable, 
high-frequency, repeat apheresis donors. While the incidence and residual risk estimates 
presented are derived from a more recent time period, we believe that they are an accurate 
proxy for the situation between 2006 and 2011. This is because donor selection policies and 
TTI screening algorithms were unchanged between the two periods, as were underlying TTI 
prevalence rates in the donor population. As such, these findings add to an already solid 
evidence base supporting repeat VNRD as the safest blood donors in settings with high 
population burdens of HIV and other TTI.31–33 Namibia’s experience also highlights the 
potential for blood services in resource limited settings in sub-Saharan Africa to support the 
broader health care sector to treat patients with hematologic and oncologic diseases and 
match demand as population increases (Namibia’s population grew by an estimated 9.7% 
between 2006 and 201130). The investments made in Namibia allowed for incremental 
reductions in PLT unit production costs, but this experience raises important questions about 
consumers’ ability or willingness to pay, as well as the need for additional funding to sustain 
current apheresis PLT production capacity, and expand PLT availability beyond the capital.
The lessons learned in Namibia present several important points for consideration by blood 
services operating elsewhere in the region, particularly those seeking to expand the 
availability of transfusion therapies to treat a broader range of clinical conditions, including 
hematologic and oncologic diseases. First, the findings of this study demonstrate that the 
size and safety of the PLT supply in a sub-Saharan African setting can be increased quickly 
and efficiently. However, decisions to develop PLT production capacity must be made in 
conjunction with an expansion of overall health care services beyond the traditional drivers 
of transfusion demand in sub-Saharan Africa (e.g. HIV, malaria, peripartum hemorrhage). 
Planners must consider logistic challenges related to PLT storage requirements and the short 
shelf life of PLT units, which may limit their utility in areas with limited distribution 
infrastructure. As demonstrated in this study, while the numbers of PLT units available 
nationally increased incrementally, most patients requiring PLT transfusions (e.g., oncology 
Pitman et al. Page 6













and hematology) continue to be referred to two large public hospitals in Windhoek, the same 
city where the PLTs were manufactured. Expanding clinical services, including PLT 
availability, to population centers in the northern, more resource-constrained part of the 
country, will be an ongoing challenge for NAMBTS and health care planners in Namibia. 
Looking ahead, Namibia’s MOHSS has already indicated that it will expand oncology 
services elsewhere in the country. In 2010, for example, radiotherapy services were 
expanded at the regional referral hospital in Oshakati, a city approximately 700 km north of 
Windhoek.34
Second, planning for PLT production must include extensive training of clinicians (on 
appropriate component use), collection staff (on apheresis collection machines), laboratory 
workers (on apheresis unit handling and quality control), and donor mobilization teams (to 
educate donors on the difference between WB and apheresis donations). Finally, particularly 
in areas where apheresis PLT production is being considered, reliance on apheresis 
equipment will require investments in maintenance and contingency planning for periods 
when the equipment may be off-line. By 2011, PLT production in Namibia was highly 
dependent on two Haemonetics apheresis machines. Although apheresis donors could agree 
to return to WB donations in the event that the machines were unavailable, contingency 
plans must also consider ongoing training for laboratory staff to ensure the quality of 
pooling procedures in facilities that no longer routinely produce pooled units.
Consideration should also be given to the long-term sustainability of PLT production 
systems, especially given the high per unit costs observed in this study. In Namibia, the 
investments that allowed NAMBTS to expand PLT production were substantially subsidized 
by grants from the US President’s Emergency Plan for AIDS Relief (PEPFAR). However, 
despite these grants, PLT unit prices remained high in Namibia, a reflection of the blood 
service’s need to recover a growing proportion of costs as the PEPFAR subsidy declined. 
While Namibia’s upper middle income economy has been able to support this cost structure, 
similar costs would likely make PLT therapy prohibitive elsewhere in the region, despite 
substantial PEPFAR investments in strengthening blood services.35,36 As PEP-FAR funding 
for blood safety scales down in Namibia and other parts of the region, mobilizing adequate 
domestic resources will become a greater challenge, as will the need to sustain the reduced 
apheresis production costs observed in this study. Domestic and international program and 
policy planners in Namibia and similar settings should continue to pay close attention to 
costs and pricing to ensure continued availability of blood and blood components and to 
ensure that cost-recovery systems remain a viable option for financial sustainability. An 
increased focus on understanding costs and the impact of reductions in external funding on 
health care service delivery has also been included in proposed US legislation to reauthorize 
the PEPFAR initiative through 2018.37 Supplemental revenue sources may also be required, 
particularly since a cost-recovery-only model may not be feasible in many sub-Saharan 
African countries. For example, to augment its non–cost-recovery revenue base, NAMBTS 
exports plasma to South Africa for fractionation. Other countries in the region may explore 
similar possibilities, but in countries that currently fund national blood transfusion services 
through government budgets and external donor support, expansion of PLT production may 
be precluded by the substantial resource mobilization requirements, as well as limited 
capacity to consume PLTs in the health care system.
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This study is subject to the following limitation. Because there is currently no system in 
Namibia to track the use of blood products within health care facilities, blood request and 
issuance data are considered a proxy for patient demand. While the figures presented here 
are likely reasonable estimates of actual PLT demand in public and private sector hospitals 
and clinics, they do not capture instances where PLTs were not available to fill a request or 
the needs of patients who cannot access a health care facility. As a result, these findings 
likely represent an incomplete estimate of PLT demand and clinical capacity to treat 
conditions requiring PLTs.
In conclusion, Namibia’s experience with growing clinical capacity for PLTs and reduced 
production costs after the introduction of apheresis technology are certainly positive signs. 
But in more resource-limited settings in the region, a longer-term approach than that 
observed in Namibia may be required before similar gains can be realized.
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ABBREVIATIONS
ID-NAT individual-donation nucleic acid test
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NAMBTS Blood Transfusion Service of Namibia
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